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In a screen designed to discover suppressors of mi-
totic catastrophe, we identified the Xenopus ortholog of
53BP1 (X53BP1), a BRCT protein previously identified
in humans through its ability to bind the p53 tumor
suppressor. X53BP1 transcripts are highly expressed in
ovaries, and the protein interacts with Xp53 throughout
the cell cycle in embryonic extracts. However, no inter-
action between X53BP1 and Xp53 can be detected in
somatic cells, suggesting that the association between
the two proteins may be developmentally regulated.
X53BP1ismodifiedviaphosphorylationinaDNAdamage-
dependent manner that correlates with the dispersal of
X53BP1 into multiple foci throughout the nucleus in
somatic cells. Thus, X53BP1 can be classified as a novel
participant in the DNA damage response pathway. We
demonstrate that X53BP1 and its human ortholog can
serve as good substrates in vitro as well as in vivo for the
ATM kinase. Collectively, our results reveal that 53BP1
plays an important role in the checkpoint response to
DNA damage, possibly in collaboration with ATM.
The eukaryotic cell cycle is a series of molecular events result-
ing in the accurate replication and segregation of the genome. To
achieve this, it is essential that the successive phases of the cell
cycle are coordinated in a precise and punctual manner, since
failure to do so may result in abnormal growth and development,
probably as a consequence of genomic instability. For this pur-
pose, cells have evolved an elaborate network of “checkpoint
controls” that monitor the proper completion of various events in
the cycle including DNA replication in S phase and chromosome
segregation during mitosis (reviewed in Ref. 1). Upon genetic
damage by any of a number of mechanisms (UV light, ionizing
radiation (g-IR), chemicals, etc.), checkpoint response pathways
become activated, leading to attenuation in cell cycle progression
and a mobilization of the DNA repair machinery.
A growing body of information on the mechanisms of check-
point control in organisms ranging from yeast to humans have
shown the importance of these pathways with respect to main-
taining genomic stability (1, 2). For example, patients with the
recessive disorder ataxia telangiectasia (AT)1 fail to delay DNA
synthesis and mitosis in response to g-IR, suggesting that the
gene responsible for this pleiotropic disease, ATM (mutated in
ataxia telangiectasia; Ref. 3), plays a major role in coordinating
the checkpoint response (4). Indeed, one of the hallmarks of AT
is a predisposition to cancer, probably as a result of the failure
to repair damaged DNA (5). In addition to ATM, many tumors
and cancer predisposition syndromes have defects in check-
point-related gene products that are phosphorylated and con-
trolled, at least in part, by the ATM kinase. This includes
BRCA1 (breast cancer gene 1), the effector kinase Cds1/Chk2,
p95/Nbs1, and p53 (6–14). BRCA1 has been reported to func-
tion in the transcriptional-coupled repair of damaged DNA,
G2/M checkpoint control, and the repair of double-stranded
DNA breaks (DSBs; Refs. 15–18). In addition, BRCA1 resides
in a large complex of proteins (BASC) dedicated to repairing
various forms of damaged DNA (19). This includes DNA mis-
match repair proteins, the BLM helicase, and the RAD50-
MRE11-NBS1 complex that is believed to function in the repair
of DSBs (21, 22). Recent work by Elledge and colleagues has
suggested that mutations in the ATM/BRCA1 pathway may
account for 10% of all cases of breast cancer (11).
The biological response to DNA damage is best understood in
both the budding and fission yeast systems (1, 24). In many
respects, the general framework of the pathways responsible
for checkpoint signaling appears to be conserved from yeasts to
humans. Here, DNA damage-sensing proteins (e.g. various Rad
gene products) transduce signals to phosphoinositide (PI)-ki-
nase like proteins (Mec1/Tel1 in budding yeast, ATM and ATR
in higher eukaryotes) that regulate effector kinases and/or
transcription factors (Rad53/Dun1 in budding yeast, Cds1/
Chk2 in higher eukaryotes; Refs. 9, 23, and 25–30). In Saccha-
romyces cerevisiae, DNA damage slows S phase progression
and can arrest cells at either the G1/S or the G2/M transitions
(31, 32). In particular, Rad9 has been shown to be a critical
factor for various checkpoint responses (31–34). In addition to
Rad9, several other budding yeast gene products have been
identified to play important roles in sensing DNA damage or
blocks in DNA replication. These include Rad53, Mec3, Rad1,
Rad24, Pol2, Dpb11, and Rfc5 and their orthologous counter-
parts in other species (1, 25, 35, 36). Although the precise
biochemical functions for many of these proteins remain un-
known, some DNA damage-sensing factors from various sys-
tems appear to possess similarities to DNA polymerase acces-
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sory factors, repair proteins, and exonucleases (25, 37–40). Such
properties might be expected for proteins whose functions are to
sense DNA damage.
One major checkpoint response in higher eukaryotes is acti-
vated upon exposure to g-IR or other agents that create DSBs.
The PI-kinase like protein ATM responds to this type of geno-
toxic insult (41) in a manner that is most likely dependent upon
DNA damage-sensing proteins. ATM-dependent phosphoryla-
tion of the p53 tumor suppressor is known to mediate cell cycle
arrest in response to DNA damage (42–44). The gene encoding
p53 is the most frequently mutated gene in all cases of human
cancer (45). p53 protein levels are activated and stabilized in
cells exposed to g-IR. Here, the protein can act as a tetrameric
transcription factor by inducing the expression of genes in-
volved with the DNA damage response (42, 44). The precise
mechanisms by which p53 is activated are not well understood
and are likely to be cell type-specific (44). In other instances,
p53 directs the apoptotic response (45). p53 protein levels are
tightly regulated by the Mdm2 protein, an E3 ubiquitin ligase
that targets p53 for degradation by the proteosome. It is be-
lieved that multiple modifications at the N and C termini
contribute to the activation of latent p53 (44, 45). Such modi-
fications include phosphorylation by ATM on serine residue 15
(7, 8) and phosphorylation of serine 20 by Cds1/Chk2 (46, 47).
Both of these modifications are believed to contribute to the
overall stability of p53, perhaps by interfering with its ability to
be degraded by Mdm2.
One protein that interacts with p53 is 53BP1 (48). 53BP1
was initially identified in a two-hybrid screen with p53 as bait
(48). Using murine p53 amino acids (aa) 73–390 fused to the
Gal4 DNA-binding domain, two human proteins were identi-
fied which bound to p53. These proteins, designated as 53BP1
and 53BP2, bound to the transcriptional activation domain of
p53 but not to a version of p53 with a point mutation (R175H)
in this domain (48). R175H generates a transcriptionally in-
competent p53 protein and has been found in patients with
cancer (45), suggesting that the binding of 53BP1 and 53BP2 is
sensitive to the conformation of p53. Additional studies have
shown that 53BP1 can enhance p53-mediated transcription of
reporter genes (58). 53BP1 possesses strong homology to the
C-terminal repeats of BRCA1 (BRCT motifs). BRCT domains
are autonomously folding modules consisting of ;100 aa and
are believed to mediate protein-protein interactions, particu-
larly with respect to proteins associated with the cell cycle and
the various aspects of DNA metabolism: replication, recombi-
nation, and repair (49–51). Other proteins possessing BRCT
motifs include budding yeast Rad9 and Dpb11, fission yeast
Crb2 and Cut5, and mammalian XRCC1 and DNA ligase IV (1,
51, 52, 53). The C-terminal 271 aa of human 53BP1, the region
encompassing the BRCT folds, was found to interact with p53
through its C-terminal BRCT repeats (48). Murine 53BP1 has
also been isolated in the two-hybrid assay when the inteferon-
inducible p202 protein is used as bait (54).
In this report, we present the isolation and characterization
of the Xenopus ortholog of human 53BP1 (X53BP1). We discov-
ered X53BP1 in a screen designed to identify suppressors of
mitotic catastrophe (negative regulators of the cell cycle) of the
fission yeast Schizosaccharomyces pombe strain SP984 (55).
We have previously exploited the mitotic catastrophe pheno-
type of SP984 to isolate Xorc2, a component of the origin rec-
ognition complex (56). This strain contains a temperature-
sensitive mutation in wee1 and a null mutation in the partially
redundant mik1 gene. Both genes encode proteins that modify
and negatively regulate the Cdc2 kinase (Cdk1), a Cdk that
functions in the progression into mitosis (57). At the nonper-
missive temperature of 35.5 °C, SP984 prematurely enters mi-
tosis due to its inability to control the precocious activation of
Cdc2. Thus, cDNA molecules capable of rescuing SP984 will
express proteins that either directly or indirectly inhibit Cdc2
activity. The complete cDNA encoding X53BP1 presented here,
in conjunction with the recently described human sequence
(58), reveals that 53BP1 proteins from both frogs and humans
are well conserved and contain numerous putative ATM family
member phosphorylation sites (59) in addition to their BRCT
motifs. Northern blotting reveals that X53BP1 expression ap-
pears largely restricted to ovaries. Consequently, we find that
the protein is abundant in eggs but much less so in somatic
cells. We present evidence that X53BP1 and Xp53 associate
throughout the cell cycle in a cell-free system, confirming the
original two-hybrid isolation of 53BP1 (48) in a specialized
cellular setting. In contrast, no association between X53BP1
and Xp53 can be detected in somatic cells, suggesting that the
interaction between these proteins is under developmental con-
trol or is restricted to germline tissue. Additionally, we find
that X53BP1 is phosphorylated in vivo in response to DNA
damage. Consistent with this, we demonstrate that both the
frog and human 53BP1 proteins serve as substrates for the
ATM kinase in vitro, particularly in an N-terminal region con-
taining numerous ATM phosphorylation motifs. In addition,
ATM phosphorylates human 53BP1 in an N-terminal region in
vivo in response to g-IR. Taken together, our data indicate that
53BP1 plays a significant role in the cellular response to DNA
damage, classifying it as an important checkpoint response
protein.
EXPERIMENTAL PROCEDURES
Isolation of the Gene Encoding X53BP1 as a Suppressor of Mitotic
Catastrophe and Cloning of the Full-length Gene—The fission yeast
strain SP984 (55) was transformed with a Xenopus laevis cDNA library
prepared in the S. pombe expression vector pAX-NMT (56, 60) by the
spheroplast method using Lipofectin (56). pAX-NMT is a fission yeast/
Escherichia coli shuttle vector and contains the S. cerevisiae LEU2 gene
for selection. From ;200,000 transformants, about 60 colonies grew at
the nonpermissive temperature of 35.5 °C on minimal media lacking
leucine and thiamine. One rescuant, pC535, was chosen for further
study. pC535 plasmid DNA was isolated and used to re-rescue SP984
from mitotic catastrophe at the nonpermissive temperature. Once the
rescuing event was confirmed, the 1.9-kb ApaI/XhoI cDNA insert of
pC535 was used to probe a Xenopus oocyte library as described previ-
ously (56, 60). This screen yielded S48-1, which contains a 5.6-kb cDNA
insert corresponding to X53BP1. To isolate the 59-end of X53BP1, se-
quence information at the 59-end of S48-1 was used to perform RACE
PCR as described below. DNA sequencing of the cDNA insert of S48-1
was done by primer walking with custom designed oligonucleotides.
The complete cDNA sequence for X53BP1 was assembled with infor-
mation generated from S48-1 and pZX-1 (see below).
Total RNA Extraction, 59-RACE PCR, and Northern Hybridization—
Various tissues as described under “Results” were collected from adult
female X. laevis frogs and immediately frozen in liquid nitrogen. Total
RNA was extracted from the various tissues or from somatic Xenopus
tissue culture (XTC) cells using Trizol (Life Technologies, Inc.) in con-
junction with DNase I. 59-RACE PCR was performed with a RACE
system (Life Technologies, Inc.) according to the manufacturer’s in-
structions. First strand cDNA synthesis was synthesized from 1.0 mg of
total XTC RNA using the GSP1 primer: 59-AAAGAAGAATCCTTAG-39.
After dC tailing, a PCR was carried out using the cDNA as a template
along with an abridged anchor primer and the nested GSP2 primer:
59-CAGCATCTTGGGAAGGAGAAACCAGAT-39. A dilution of the orig-
inal PCR was reamplified with a nested GSP3 primer: 59-CAGAAGGAT-
GGAGTAGGCGCAAACTGT-39. All reactions were carried out under the
recommended conditions of the supplier. PCR products were electrophore-
sed on 1.0% agarose gels, and a target band of ;0.9 kb was gel purified
and ligated into the pGEM-T vector (Promega), creating pZX-1. DNA
sequencing of pZX-1 was performed on both strands by primer walking
using an ABI sequencer and shown to unambiguously overlap with S48-1.
For Northern hybridization, 10 mg of total RNA was separated on a
1.0% formaldehyde agarose gel with a 0.4–9.5-kb RNA ladder (Life
Technologies, Inc.). RNA was transferred onto Hybond-N1 membrane
(Amersham Pharmacia Biotech) by capillary elution with 203 SSC and
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fixed with 0.5 N sodium hydroxide. The membrane was prehybridized at
65 °C for 15 min in rapid hybridization buffer (Amersham Pharmacia
Biotech) and hybridized with a 0.9-kb probe corresponding to the ex-
treme 59-end of X53BP1 or a 1.2-kb fragment derived from Xenopus
EF-1a (62) for 2 h at 65 °C in rapid hybridization buffer. The membrane
was washed for 15 min at 65 °C for 15 min in 23 SSC, 13 SSC, and
0.13 SSC with 0.1% SDS and exposed to film.
Cell-free Extracts—Xenopus cell-free extracts were prepared by the
method of Murray (53). Interphase extracts were generated by the addi-
tion of 0.4 mM calcium chloride to cytostatic factor (CSF)-arrested extracts
in the presence of cycloheximide (100 mg/ml) and allowed to proceed for 30
min at 25 °C. The entry into interphase was verified through either H1
kinase assays or observation of nuclear envelope formation.
Recombinant Proteins and Antibody Production—To produce poly-
clonal rabbit antibodies against X53BP1, we generated a GST fusion
protein between GST and residues 1652–2055 of X53BP1 by PCR am-
plification with a high fidelity DNA polymerase, creating GST-XBP1–5.
This amplified X53BP1 fragment was ligated in frame into pGEX4T-1
(Amersham Pharmacia Biotech) on a BamHI fragment. The resulting
recombinant was confirmed and used to transform DH10B cells. Protein
expression was induced by the addition of 0.1 mM isopropyl-1-thio-b-D-
galactopyranoside at 25 °C for 3 h. Soluble GST-XBP1–5 protein was
affinity purified on glutathione-agarose. The purified protein was used
as antigen for injection into rabbits (Covance). All other 53BP1 fusion
proteins were generated in a similar manner. Various bleeds were
tested for antibody production via immunoblotting with a chemilumi-
nescent system (Amersham Pharmacia Biotech), and those that were
positive were used to affinity-purify aX53BP1. Anti-GST antibodies
were selectively removed from the serum by adsorption onto GST-
loaded Sepharose beads. The unbound antibodies against X53BP1 were
affinity-purified as described (72) with GST-XBP1–5 protein coupled to
CNBr-Sepharose (Amersham Pharmacia Biotech) at a concentration of
1.0 mg/ml as per the manufacturer’s instructions. For the generation of
antibodies against Xp53, the full coding sequence to Xp53 was isolated
from a Xenopus cDNA library (60), amplified with a high fidelity DNA
polymerase, and ligated in frame into pGEX4T-1 for protein expression.
Soluble GST-Xp53 was expressed in DH10B bacterial cells and affinity-
purified as described above. The isolated protein was used as an antigen
to generate polyclonal antibodies.
DNA Damage-inducible Phosphorylation of X53BP1—XTC cells were
cultured in Liebovitz’ L-15 medium (Life Technologies, Inc.) supple-
mented with 10% fetal calf serum and antibiotics. 36 plates were grown
to 60% confluency. One half of the plates was treated with 10 Gy of g-IR
with a cesium irradiator, and the other half was left untreated. Samples
were allowed to recover for 1 h post-treatment. After the recovery
period, the cells were collected, washed with phosphate-buffered saline
(PBS), and lysed on ice with PBS supplemented with 1% TX-100, 1%
Nonidet P-40, 2 mM CaCl2, and a mixture of protease inhibitors. Clar-
ified supernatants were treated for 1 h with aX53BP1 (or aXp53 in
some cases) that had been covalently coupled to protein A-Sepharose.
The immunoprecipitates were subsequently washed four times with
EB1 buffer (20 mM b-glycerol phosphate, 10 mM Hepes, 1% Nonidet
P-40, and 25 mM sodium fluoride, pH 7.5). The beads were further washed
twice in an EB1 buffer without detergent and sodium fluoride. Finally,
the samples were washed twice in l phosphatase buffer (50 mM Tris, 0.1
mM EDTA, 5 mM dithiothreitol, 0.01% Brij 35, pH 7.5) and split in half.
One half was treated with phosphatase buffer and the other was supple-
mented with 1.0 unit of l-phosphatase (New England Biolabs), incubated
at 30 °C for 30 min, and loaded onto Novex 3–8% acrylamide gels.
Indirect Immunofluorescence in XTC Cells—XTC cells were grown on
polylysine-treated coverslips to 60% confluency in Liebovitz’ L-15 me-
dium and processed for indirect immunofluorescence with aX53BP1 as
follows. Cells were fixed with 2% paraformaldehyde in 66% phosphate-
buffered saline, pH 7.4, and permeabilized with 0.05% saponine, 1.5 mM
NH4Cl in phosphate-buffered saline. Permeabilized cells were treated
with primary antibody for 1 h, washed three times in phosphate-buff-
ered saline without paraformaldehyde, and incubated with an anti-
rabbit IgG conjugated to fluorescein isothiocyanate for 1 h (Pierce).
Mounted coverslips were viewed under oil at 1003 magnification and
photographed using an Olympus BX60 microscope equipped with a Spot
digital camera (Diagnostics Instruments) interfaced. Images were
transferred and processed into Adobe Photoshop 5.0.
ATM Kinase Assays—In vitro ATM kinase assays were performed
essentially as described previously (7, 8). Briefly, 293T cells were trans-
fected with constructs expressing either the full-length ATM gene or a
kinase-defective version of the enzyme. The expressed proteins were
immunoisolated with M2/M5 FLAG antibodies (Sigma) coupled to pro-
tein A/G-Sepharose (Santa Cruz Biotechnology, Inc., Santa Cruz, CA)
and incubated with candidate GST fusion proteins containing various
segments of either the Xenopus or human 53BP1 proteins. Approxi-
mately 1 mg of affinity-purified, candidate substrate protein was incu-
bated in ATM kinase buffer (8) with 10 mCi of [g-32P]ATP for 30 min at
30 °C with constant agitation. In vivo phosphorylation of 53BP1 was
measured in a transient transfection assay using 293T cells. Transfec-
tions were performed with Lipofectin (Life Technologies, Inc.). Human
53BP1 residues 1–524 were fused in frame to pFLAG-NLS lox (11),
creating plasmid pZX-12. pZX-12 encodes FLAGBP1–124. 2.5 mg of
pZX-12 was transfected alone or cotransfected along with an equal
amount of plasmid expressing either the wild type or kinase-dead
version of ATM. After 48 h posttransfection, the cells were treated with
either 0 or 50 Gy of ionizing radiation using a cesium irradiator. After
a 1-h recovery, the cells were harvested, processed for immunoprecipi-
tation, electrophoresed on 6% SDS gels, and transferred overnight in
preparation for Western analysis with anti-FLAG M2/M5 antibodies (Sig-
ma). FLAGBP1–1524 was visualized by Western blotting with aX53BP1
and the ECL detection system (Amersham Pharmacia Biotech).
RESULTS
Identification of X53BP1 as a Suppressor of Mitotic Catas-
trophe—To identify potential negative regulators of the cell
cycle, we rescued the fission yeast mitotic catastrophe strain
SP984 (55) with a Xenopus cDNA library prepared in the pAX-
NMT S. pombe expression vector (56, 60). At the nonpermissive
temperature of 35.5 °C, SP984 is deficient in Cdc2-specific ty-
rosine kinase activity, an inhibitory modification. This results
in a precocious activation of Cdc2 during interphase, causing
premature mitotic entry and cell death. We have previously
used this method to identify Xorc2, a member of the Xenopus
FIG. 1. Rescuing of a mitotic catastrophe strain (SP984, mik::ura41, wee 1–50 leu1–32 ade6–210 ura4-D18 h1N) by an X. laevis cDNA
encoding X53BP1. A, schematic representation of the screen utilized to isolate pC535, a fission yeast/E. coli shuttle vector (pAX-NMT) containing
a 1.9-kb ApaI/XhoI cDNA corresponding to the C-terminal region of X53BP1. See “Experimental Procedures” for details. B, suppression of mitotic
catastrophe by pC535. SP984 was transformed with either the pAX-NMT vector only, rescuant pC535, or the wild type wee1 gene cloned into
pAX-NMT, grown for 6 days at the restrictive temperature of 35.5 °C, and streaked out on agar plates.
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origin recognition complex (56). A second rescuant described
here, pC535 (Fig. 1), was found to contain a 1.9 kb ApaI/XhoI
cDNA fragment encoding for the C-terminal region of the frog
53BP1 ortholog (X53BP1). 53BP1 was originally described as a
human protein capable of binding to the central transactivation
domain of murine p53 in a two-hybrid assay (48). The largest
X53BP1 plasmid capable of rescuing SP984 was found to con-
tain a 4-kb ApaI/XhoI fragment encoding for the C-terminal
region of X53BP1. All rescuing cDNAs of X53BP1 possess the
two repeating BRCT motifs found at the extreme C terminus
(Fig. 2A). pC535-expressing mutant cells divided normally and
exhibited neither an obvious wee nor elongated phenotype (not
shown). Despite this, the rescued cells still entered mitosis
inappropriately in the presence of 10 mM hydroxyurea at the
restrictive temperature. Thus, despite its formal classification
as a negative regulator of the cell cycle in fission yeast, the
expression of X53BP1 is not sufficient to restore the replication
checkpoint defect characteristic of SP984. The precise reasons
for why X53BP1 rescues SP984 from mitotic catastrophe re-
main to be determined.
Cloning and Characterization of X53BP1—Because human
53BP1 is comprised of 1972 amino acids (58), we assumed that
the frog ortholog would be of a similar size. If so, then it was
clear that rescuant pC535 was only a partial cDNA clone. In an
attempt to isolate the full coding sequence of X53BP1, we used
the 1.9-kb ApaI/XhoI fragment from pC535 to screen a cDNA
library derived from X. laevis oocytes (60). From 1 million
library clones, 22 cDNAs encoding various portions of X53BP1
were isolated. The largest isolate, S48-1, was sequenced and
found to be an incomplete cDNA, since it contained a 5.6-kb
ApaI/XhoI fragment. To isolate the 59-end of X53BP1, we per-
formed a PCR RACE experiment (Life Technologies, Inc.) with
RNA isolated from the XTC somatic cell line using sequences
derived from the 59-end of S48-1. A 0.9-kb fragment was suc-
cessfully isolated, sequenced on both DNA strands, and shown
to encode the N-terminal region of X53BP1. Importantly, this
RACE product possesses an initiating methionine codon that
properly aligns with the proposed first methionine of human
53BP1 (Ref. 58; Fig. 2A). This methionine residue is also pre-
ceded by an in-frame stop codon (UAG) six nucleotides up-
stream of the ATG codon (not shown). Moreover, this fragment
contains a significant and unambiguous 39 overlap to the 59-end
of S48-1 (not shown). The full-length cDNA for X53BP1 is ;6.5
kb long and contains 59- and 39-untranslated regions of 45 and
FIG. 2. Characterization of the gene
encoding X53BP1. A, amino acid align-
ment of the N termini of Xenopus and
human 53BP1 proteins. The frog and hu-
man 53BP1 proteins (GenBankTM acces-
sion numbers AF281071 and AF078776,
respectively) were compared via a BLAST
program (NCBI) as shown. Potential
ATM family member phosphorylation
sites (59) are highlighted in black and are
also represented by the vertical hatched
lines. B, Northern blot of X53BP1 tran-
scripts in various X. laevis tissues. 10 mg
of total RNA was isolated and processed
for Northern blotting analysis as de-
scribed under “Experimental Proce-
dures.” The major X53BP1 transcript of
6.5 kb is present in abundance in ovaries
and to a lesser extent in the kidney-de-
rived XTC cell line. Prolonged exposures
also reveal a minor amount of transcript
in the heart. A second, minor transcript
migrating around 4.5 kb is also present.
53BP1 and the DNA Damage Response 2711
62 nucleotides (excluding the poly(A) tail), respectively. The
complete sequence of X53BP1 encodes a protein of 2104 amino
acids (predicted mass of 231.3 kDa) with significant homology
to the 1972-residue human 53BP1 protein and has been depos-
ited in GenBankTM (accession number AF281071).
Both 53BP1 proteins possess two repeating BRCT motifs (49,
50, 61) at their respective C termini. Additionally, the frog and
human 53BP1 orthologs contain numerous “(S/T)Q” motifs,
some of which are conserved, particularly in their N termini,
where there is clustering (Fig. 2A). Such sequence elements
have been shown to formulate strong recognition determinants
for the ATM kinase and its related family members ATR and
DNA-PK (59). In addition, X53BP1 contains four (S/T)PX(R/K)
motifs that reside in potential Cdk recognition sites (not
shown). Thus, both the frog and human 53BP1 proteins possess
sequence features suggestive of functions in checkpoint control
during the biological response to DNA damage.
To further understand the role of X53BP1 in Xenopus, we
analyzed X53BP1 transcripts by Northern blotting (Fig. 2B). 10
mg of total RNA was isolated from various female frog tissues
with Trizol and electrophoresed on 0.8% agarose gels. The gels
were processed for Northern analysis with a 0.9-kb DNA probe
specific for the 59-end of X53BP1. As a loading control, a 1.1-kb
PstI probe specific for Xenopus EF-1a was used (not shown).
These messages have been shown to be relatively constant in
Xenopus. (62). Our results clearly indicate that X53BP1 tran-
scripts appear to be abundant in ovaries but not in the other
tissues that were sampled (Fig. 2B). Unlike Xenopus, the hu-
man 53BP1 transcripts were detected in all tissues sampled
(48). As is also the case for human 53BP1, two transcripts can
be detected (48). However, in contrast to the frog messages of
;7.0 and 4.5 kb (Fig. 2A), the human 53BP1 messages are 11.0
and 7.0 kb (48). X53BP1 mRNA is detectable, albeit at much
reduced levels relative to the ovaries, in heart tissue and the
somatic XTC cell line. The high X53BP1 transcript levels in
ovarian tissue, as has also been demonstrated for Xp53 (63),
are consistent with the maternal stockpiling that is seen for
many proteins, including X53BP1 protein (see below).
Association of X53BP1 and Xp53 in Cell-free Extracts and
Somatic Cells—To characterize X53BP1 further, we raised
polyclonal antibodies that react against a glutathione S-trans-
ferase (GST) fusion protein encoding amino acids 1652–2055
(GST-XBP1–5), which reside near the C terminus of X53BP1.
The soluble GST-XBP1–5 protein was purified on glutathione-
agarose (Sigma), eluted with reduced glutathione as described
(64), and injected into rabbits for polyclonal antibody produc-
tion. Affinity-purified antibodies that react against X53BP1
(aX53BP1), but not against GST, were isolated as described
under “Experimental Procedures” and used to examine the
protein in cell-free extracts derived from Xenopus eggs (Fig.
3A). Such extracts have been shown to recapitulate the major
events of the cell cycle including DNA replication and mitosis
(53, 56, 60). Xenopus eggs are arrested in metaphase of meiosis
II (M phase), a mitotic-like state, through the action of CSF.
FIG. 3. Analysis of X53BP1 in cell-free extracts and somatic XTC cells. A, immunoblotting of cell cycle staged extracts or somatic XTC cells
for X53BP1. 10ml (;500 mg of protein) from either mitotic (CSF; lanes 1 and 2) or interphase extract (lane 3) was immunoprecipitated with either
a control IgG (lane 1) or aX53BP1 (lanes 2 and 3), electrophoresed on 6% SDS gels, and immunoblotted with affinity-purified aX53BP1. X53BP1
migrates at ;300 kDa. Lane 4, XTC extract (;5–10 mg of protein) was immunoprecipitated with aX53BP1 and immunoblotted for X53BP1 with
aX53BP1. B, coimmunoprecipitation of Xp53 with aX53BP1 in cell-free extracts. 50 ml of either CSF-arrested (M; lanes 1 and 2) or interphase-
arrested (I; lanes 3 and 4) extracts was immunoprecipitated with a control IgG (lanes 1 and 3) or aX53BP1 (lanes 2 and 4) and processed for
immunoblotting for Xp53 with either aXp53 or in some cases the Xenopus p53 antibody 2274 (66). C, coimmunoprecipitation of X53BP1 with
aXp53. 50 ml of either CSF-arrested (M; lanes 1 and 2) or interphase-arrested (I; lanes 3 and 4) extracts were immunoprecipitated with
affinity-purified aXp53 or a control rabbit IgG (lanes 1 and 3) and processed for immunoblotting with aX53BP1 (lanes 2 and 4). Visualization of
target antigens was conducted with a chemiluminescent system (ECL; Amersham Pharmacia Biotech). D, coimmunoprecipitation of X53BP1 and
Xp53 in XTC cells. XTC cells were treated with either 0 or 10 Gy of g-IR and allowed to recover for 1 h prior to making extracts. XTC extracts were
immunoprecipitated with aXp53 (lanes 1 and 2) or aX53BP1 (lanes 3 and 4) and immunoblotted for either X53BP1 or Xp53 as shown.
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X53BP1 is present in both M phase and interphase extracts in
equivalent amounts as revealed by Western blotting (Fig. 3A).
Like its human counterpart, X53BP1 migrates aberrantly on
SDS gels (58). The predicted molecular mass of X53BP1 is 231
kDa, but both the M phase and interphase forms appear to
migrate around 300 kDa (Fig. 3A). X53BP1 was often detected
as a diffuse set of bands (Fig. 3A), consistent with the protein
undergoing posttranslational modifications, possibly phospho-
rylation, throughout the cell cycle. To demonstrate that
X53BP1 is present in somatic cells, in addition to embryonic
extracts, we examined the protein in XTC cells, a somatic cell
line (79). We immunoprecipitated X53BP1 from XTC cells with
aX53BP1 and examined the presence of the protein by Western
blotting. Our results show that X53BP1 is present in the XTC
cell line but at much reduced levels relative to the embryonic
protein (Fig. 3A). We estimate that the concentration of
X53BP1 in Xenopus eggs is 100 nM and less than 10 nM in
somatic cells. Unlike the diffuse banding pattern often seen for
embryonic X53BP1, the somatic protein species appears to
migrate as a much sharper band in 6% SDS gels (Fig. 3A).
Because 53BP1 was initially identified as a p53-binding pro-
tein, we investigated the relationship between X53BP1 and the
Xenopus p53 protein (Xp53; Refs. 65–67) in cell-free extracts
derived from frog eggs. Xp53 is highly expressed during oocyte
development (68). Xenopus eggs contain an abundance of Xp53
protein, which has been shown to possess the same biochemical
properties of its human counterpart (63, 66, 69). Despite this,
there is no transcription occurring in eggs, since development
relies upon maternal stores of protein until zygotic transcrip-
tion occurs at the midblastula transition (70). Thus, the func-
tional significance of Xp53 in early embryonic development is
not clear, although roles for the protein during this period have
been suggested. For example, microinjection of Xp53 mRNA
into early cleavage stages interferes with normal frog develop-
ment (67). In addition, inhibition of Xp53 function via ectopic
expression of either a dominant negative Xp53 or its inhibitor
X-dm2 results in an early block to differentiation (71).
To address the nature of any X53BP1/Xp53 interactions, we
performed reciprocal coimmunoprecipitation experiments (Fig.
3B) from cell-free extracts derived from unfertilized eggs. For
this purpose, we generated polyclonal antibodies against the
frog p53 protein (aXp53). Coimmunoprecipitation experiments
were performed with either aX53BP1, aXp53, or a control
rabbit IgG. In some instances, we immunoblotted for Xp53 with
antibody 2674 (a2674), a polyclonal Xp53 antiserum described
previously (66). We found that aXp53 and a2674 gave similar
results (not shown). For immunoprecipitations, all antibodies
were covalently linked to protein A beads with dimethylpime-
limidate as described previously (72). After a 1-h incubation at
4 °C in either CSF-arrested or interphase extracts, the beads
were collected by brief centrifugation, thoroughly washed, and
then resuspended in SDS sample prior to loading on SDS gels.
The results clearly demonstrate that X53BP1 and Xp53 asso-
ciate with each other throughout the cell cycle in cell-free
extracts (Fig. 3, B and C). Xp53 can be detected in X53BP1
immunoprecipitates, and X53BP1 is present in Xp53 immuno-
precipitates as shown. Neither of these two proteins are pres-
ent with the control IgG, indicating that the association be-
tween X53BP1 and Xp53 is specific. Thus, consistent with
previous studies in mammals (48, 58), X53BP1 and Xp53 form
complexes in Xenopus. Interestingly, such complexes are pres-
ent throughout the cell cycle in both M phase and interphase.
To further characterize the interaction between X53BP1 and
Xp53, we performed reciprical coimmunoprecipitations in so-
matic XTC cells extracts. Immunoprecipitations from these
extracts were processed in the same manner as described for
the egg extracts. Unexpectedly, no interaction can be detected
between X53BP1 and Xp53 in somatic cells (Fig. 3D). Because
p53 is known to be involved in the response to g-IR DNA
damage, we assayed for a potential X53BP1/Xp53 interaction
in the presence of this form of genotoxic stress. As observed
before, no interaction between the two proteins can be seen.
Similar observations have also been made for 53BP1 and p53 in
human cell lines.2 Thus, these data suggest that the associa-
tion between X53BP1 and Xp53 is under developmental control
or is restricted to germline tissue.
DNA Damage-inducible Phosphorylation of X53BP1—Many
proteins involved in checkpoint signaling are modified in re-
sponse to DNA damage. These include the ATM-dependent
phosphorylation of BRCA1, Cds1/Chk2, p53, and p95/Nbs1 (8,
9, 11–14). Given the relationship of 53BP1 to p53, the presence
of its two-repeating BRCT domains, and its potential ATM
phosphorylation sites, X53BP1 appeared as a strong candidate
for modification by phosphorylation in response to DNA dam-
age, particularly g-IR. To address this issue, we examined the
nature of X53BP1 in Xenopus somatic XTC cells that had been
exposed to g-IR. XTC cells, grown on plates to 60% confluency,
were treated with either 0 or 10 Gy of g-IR with the use of a
cesium irradiator. After a brief recovery period, the cells were
collected, lysed, and immunoprecipitated with aX53BP1 that
had been linked to protein A beads. After thoroughly washing
the pellet, the samples were split into two equal portions. One
part was treated with buffer, and the second was treated with
l phosphatase. After incubation, the samples were processed
for electrophoresis on 3–8% gradient gels. In the absence of
g-IR, X53BP1 migrates at ;300 kDa (Fig. 4, lanes 1 and 2).
When exposed to 10 Gy of g-IR, X53BP1 appears as even a
slower migrating form (Fig. 4, lane 3). This retarded form of
X53BP1 can be reversed back to its basal state through treat-
ment with l-phosphatase (Fig. 4), indicating that the g-IR-
induced modification of the protein is due to phosphorylation.
Additionally, X53BP1 is also modified via phosphorylation in
the absence of DNA damage, since it appears to have a slightly
slower mobility in gradient gels relative to the l-phosphatase-
treated sample (Fig. 4, compare lanes 1 and 2). Other factors,
such as cyclin-dependent kinases, may be responsible for this.
Taken together, our results establish X53BP1 as a new mem-
ber of the g-IR DNA damage response pathway.
Subcellular Localization of X53BP1 in Somatic Cells by In-
direct Immunofluorescence—Previous indirect immunofluores-
2 T. Halazonetis, personal communication.
FIG. 4. DNA damage-dependent phosphorylation of X53BP1 in
vivo. XTC cells were treated with either 0 (lanes 1 and 2) or 10 Gy of
g-IR (lanes 3 and 4). Lysed supernatants were immunoprecipitated
with aX53BP1 and split into two equal halves. One half received buffer
only (lanes 1 and 3), and the other was treated with 1.0 units of
l-phosphatase (lanes 2 and 4). Immunoprecipitates were electrophore-
sed on 3–8% gradient gels and immunoblotted with aX53BP1 as shown.
Various electrophoretic forms of X53BP1 are indicated by the brackets.
The position of the 209-kDa marker (myosin heavy chain) is indicated
with an arrow.
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cence (IF) experiments with human 53BP1 revealed that the
protein can be found in both the cytoplasm and nucleus (58).
The nuclear immunostaining observed for 53BP1 in these stud-
ies revealed that the protein could be found in a homogenous or
punctate pattern. However, because these studies were done
with cells that had been transfected with 53BP1, the subcellu-
lar localization of the endogenous protein could not be unam-
biguously determined. We used IF to determine the subcellular
localization of the endogenous frog X53BP1 protein in XTC
cells. Asynchronous cells were grown to 60% confluency on
polylysine-coated coverslips and processed for IF analysis with
affinity-purified aX53BP1 and a fluorescein-conjugated sec-
ondary IgG. Staining with either secondary antibody alone or
with other nonspecific IgG molecules produced no signal (not
shown). This, in conjunction with the fact that aX53BP1 rec-
ognizes one major band in XTC extracts (Fig. 3A), suggests that
the immunostaining data specifically represents X53BP1. The
staining pattern for X53BP1 agrees with the previously re-
ported pattern for human 53BP1 (58). X53BP1 possesses a
diffuse cytoplasmic staining pattern (Fig. 5, A and B). More-
over, X53BP1 appears to localize to a small number of large
nuclear foci (1–3) in about 20% of the cells (Fig. 5A, see arrows).
To observe any changes in the subcellular localization of
X53BP1 that may occur in response to DNA damage, we ex-
posed XTC cells to 10 Gy of g-IR. After a recovery period, the
cells were processed for IF. After examining a few hundred
cells, it appears that many more, smaller foci are present in
nuclei that have been exposed to the DNA-damaging agent
(Fig. 5B, see arrows), suggesting that X53BP1 is redistributed
within the nucleus in response to g-IR. These foci are absent in
nonirradiated samples. Since about 20% of the examined cells
possess multiple nuclear foci, this suggests that the focal local-
ization of X53BP1 may occur at a discrete point(s) within the
cell cycle (i.e. S phase).
ATM-dependent Phosphorylation of 53BP1—The sequences
of both X53BP1 and 53BP1 from humans suggest that the
proteins may serve as effective substrates for members of the
ATM kinase family (e.g. ATM, ATR, and DNA-PK). Both the
frog and human 53BP1 proteins possess numerous (S/T)Q mo-
tifs, which are known to be the minimal, essential determi-
nants for recognition by ATM family members (59). X53BP1
possesses 32 of these potential recognition motifs, whereas the
human ortholog has 30 such sites. Several of these sites are
clustered in the N-terminal region of X53BP1 (Fig. 2A). Such
clustering is also evident in the N-terminal region of human
53BP1 (Ref. 58; Fig. 2A). Clustered (S/T)Q motifs have been
suggested to formulate a strong recognition determinant for
ATM and its related PI-like kinases (11, 59). Given these po-
tential phosphorylation sites and the fact that X53BP1 is phos-
phorylated in response to g-IR DNA damage, we asked if
X53BP1 could serve as a substrate for the ATM kinase. It has
been well established that ATM is activated in response to this
type of genotoxic insult (7, 8). To show this, we generated a
series of GST fusion proteins spanning X53BP1 (Fig. 5). Such
an approach has been previously adopted to demonstrate the
ATM and Chk2-dependent phosphorylation of BRCA1 (11, 77).
To perform this assay, 293T cells were transfected with a
FLAG-tagged cDNA encoding either the wild type ATM gene
(WT) or a kinase-dead (KD) version of the enzyme (7, 8). After
48 h, the cells were harvested and lysed in TGN buffer (8).
After a preclearing step with protein G-agarose beads, either
WT or KD ATM protein was immunoisolated, extensively
washed as described (8, 11), and incubated with candidate
GST-X53BP1 fusion substrate proteins in the presence of ra-
diolabeled ATP.
Our results demonstrate that GST fragment 1 (GST-
XBP1–1) and GST-XBP1–4 serve as good in vitro substrates for
ATM but not the KD version of the protein (Fig. 4). On the
other hand, GST-XBP1–2, GST-XBP1–3, and GST-XBP1–5 ap-
pear to be essentially refractory to ATM-dependent phospho-
rylation in this assay despite the fact that these sequences
contain several potential ATM recognition sites. GST-XBP1–1
encodes for aa residues 1–338 in X53BP1, a region of the
protein that contains 11 putative ATM phosphorylation sites
(Fig. 2A). Interestingly, GST-XBP1–1 migrates around 100
kDa on 6% SDS gels despite the fact that its predicted molec-
ular mass is ;65 kDa. Such anomalous behavior in SDS gels
has also been observed for human 53BP1 (Ref. 58; Fig. 6).
X53BP1 has a predicted mass of 231 kDa but migrates at ;300
kDa (Figs. 3A and 4). Phosphorylation of GST-XBP1–1 by ATM
appears to generate a doublet pattern, suggesting that the
enzyme targets multiple residues within the first 338 amino
acids of X53BP1 (Fig. 4). In contrast, we find that ATM-depend-
ent phosphorylation of GST-XBP1–4, a fusion protein encoding
X53BP1 residues 1201–1657, generates an apparent singlet,
despite the fact that there are eight (S/T)Q motifs within this
region. It is interesting to note that four of the potential phos-
phorylation sites of GST-XBP1–4 reside in a cluster spanning
residues 1272–1327 (not shown). Taken together, these results
clearly demonstrate that X53BP1 is phosphorylated in vitro at
multiple places by the ATM kinase.
To further investigate the relationship between ATM phos-
phorylation and 53BP1, we created a GST fusion protein be-
tween human 53BP1 residues 1–524 (HBP1–524) and assayed
for its potential to be recognized as a substrate by the ATM
kinase. Human 53BP1 possesses 11 potential ATM kinase rec-
ognition motifs within this region of the protein (Ref. 58; Fig.
2A). Additionally, HBP1–524, like its amphibian counterpart,
migrates much slower than its predicted molecular weight.
Thus, N-terminal sequences of both the frog and human 53BP1
proteins contribute to the anomalous mobility that has been
observed for these proteins in SDS gels (58). Nevertheless,
HBP1–524 serves as a very good substrate for ATM in our in
vitro assay and appears as a phosphorylated doublet (Fig. 7A).
Because the N-terminal regions of both Xenopus and human
53BP1 proteins appear to be phosphorylated by ATM in vitro,
we assessed the ability of the N-terminal region of human
53BP1 to serve as a potential substrate for ATM in vivo. Hu-
man 53BP1 residues 1–524 were cloned in frame into pFLAG-
NLS lox (11), generating plasmid pZX-12. This plasmid ex-
presses residues 1–524 fused to an N-terminal nuclear
localization signal and to a FLAG epitope tag (FLAGBP1–524).
As previously seen for this segment of 53BP1, H53BP1–524
also ran aberrantly on SDS gels. ATM-dependent phosphoryl-
ation was assessed in a transient transfection assay using 293T
FIG. 5. Subcellular localization of X53BP1 during the DNA
damage response. XTC cells were processed for indirect immunoflu-
orescence with aX53BP1 as described under “Experimental Proce-
dures” in the absence of DNA damage (A) or in the presence of 10 Gy of
g-IR (B). The green area (fluorescein isothiocyanate) represents stain-
ing specifically associated with aX53BP1, and the blue represents nu-
clear DNA staining with Hoescht 33258. The scale bar represents 25
mm.
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cells. These cells were transfected with pZX-12 alone or in
combination with plasmids encoding either the ATM WT or KD
protein. After 48 h, the cells were exposed to either 0 or 50 Gy
of g-IR with a cesium irradiator, allowed to recover, and then
processed for immunoprecipitation and immunoblotting anal-
ysis with the M2/M5 FLAG-specific antibodies. If 53BP1 is
phosphorylated by g-IR activated ATM, then slower mobility
forms of 53BP1 might be expected to be seen in the form of
shifts in the molecular weight of the protein. In the absence of
g-IR, pZX-12-transfected 293T cells were found to generate
multiple forms of H53BP1–524 (Fig. 7B, lane 1), reminiscent of
the behavior often observed for X53BP1 in cell-free extracts
(Fig. 3A). Because these bands are reversible through treat-
ment with l phosphatase enzyme (Fig. 7B, lane 2), it appears
that H53BP1–524 is phosphorylated in its basal state by en-
dogenous enzymes within 293T cells. Despite this background
level of phosphorylation for FLAGBP1–524, higher molecular
weight, shifted forms of the protein are clearly apparent in
g-IR-treated samples that have been cotransfected with ATM
WT but not with a plasmid encoding the kinase-defective en-
zyme (Fig. 7B, lane 7; see arrow). Such proteins often appear as
diffuse species. We confirmed that these proteins are phospho-
rylated species of 53BP1, since treatment with l-phosphatase
completely reverses the induced mobility shift. Collectively, our
results suggest that 53BP1 is a targeted by ATM during the
DNA damage response.
DISCUSSION
The accurate replication and segregation of the genetic ma-
terial is tightly controlled during the cell cycle. It has become
increasingly clear that cells that cannot properly coordinate
these processes within the framework of the cell cycle place
themselves at great risks for developing chromosomal instabil-
ities. Consequently, the faithful transmission of the genetic
material will be compromised, leading to a number of potential
pathologies including cancer (2). Cells respond to various forms
of DNA damage by halting cell cycle progression and activating
the machinery responsible for mending disabled DNA (1, 31,
32). One form of DNA damage is DSBs, which occur spontane-
ously during S phase, meiosis, and V(D)J recombination and
through environmental agents such as g-IR. As such, recent
advancements into the mechanisms of checkpoint control in a
range of organisms from yeast to humans have led to unex-
pected connections between DNA recombination/repair pro-
teins and cell cycle control (22). The inability to repair DSBs
poses a significant threat to genomic instability. Such genetic
frailties have been observed in cells with mutations in a variety
of genes encoding proteins that participate in the biological
response to this type of DNA damage. Many of the proteins
involved in the biological response to g-IR are controlled in
some manner through ATM-dependent phosphorylation. ATM
phosphorylates numerous substrates, many of which partici-
pate in cell cycle control and repairing DSBs. These include
BRCA1, Cds1/Chk2, p95/Nbs1, and p53 (7, 8, 10, 11, 13, 14, 77).
In this study, we have characterized 53BP1 proteins from both
frog and human. Our data classify 53BP1 as a component in the
DNA damage response pathway.
We identified X53BP1 in a genetic screen designed to un-
cover suppressors of mitotic catastrophe. We observed that
X53BP1-expressing cDNAs could rescue SP984 as effectively as
wee1, the natural complementing gene. X53BP1 cDNAs were
found to rescue SP984 only when expressed under the highly
inducible nmt1 promoter, implying that high levels of X53BP1
are responsible for the rescued phenotype. Additionally, all
rescuing cDNAs encoded for X53BP1 derivatives possessing the
C-terminal BRCT repeats. Thus, it is possible that overexpres-
sion of these repeated BRCT motifs leads to the titration of a
cellular factor(s) that can either directly or indirectly influence
the activity of Cdc2 and hence the ability of SP984 to undergo
premature mitosis. Overexpression of X53BP1 in SP984, how-
ever, is not sufficient to restore the replication checkpoint
defect associated with the strain as the rescued cells undergo a
mitotic catastrophe when exposed to hydroxyurea. It is there-
fore unlikely that X53BP1 suppresses the growth defect of
SP984 through the activation of the replication checkpoint.
Thus, the precise reasons for the ability of X53BP1 to rescue
SP984 remain unknown, although it is interesting to note that
a yeast strain deficient in a checkpoint mechanism can be
rescued by a protein that itself appears to function in a check-
point response to DNA damage. Whatever the case, it is clear
that X53BP1, when expressed in SP984, influences the growth
of the yeast. Perhaps this accounts for its fortuitous isolation.
Interestingly, it has been reported that the C-terminal BRCT
repeats of BRCA1 can also confer growth-suppressing proper-
ties in budding yeast (73). Although the mechanism of this
suppression is unknown, it was shown to require intact BRCT
motifs. Despite these observations, the transformation of
pC535 into wild type yeast cells does not impair the growth of
the strain.
Unlike human 53BP1 transcripts, X53BP1 is highly ex-
pressed in ovarian tissue as revealed by Northern blotting with
Xenopus total RNA. Consequently, X53BP1 is abundant in
unfertilized eggs. The levels of X53BP1 do not appear to be cell
FIG. 6. ATM-dependent phosphorylation of X53BP1 in vitro. A,
schematic representation of GST-XBP1 fusion substrates utilized in an
assay for ATM kinase activity (7, 8). Hatched lines represent approxi-
mate positions of (S/T)Q motifs. Five fusion proteins as shown were
created for the assay. The following aa residues are encoded for by the
GST-XBP1 fusion proteins. GST-XBP1–1, aa 1–338; GST-XBP1–2, aa
393–821; GST-XBP1–3, 815–1206; GST-XBP4, 1201–1657; GST-XBP5,
1652–2,055. B, affinity-purified fusion proteins were processed for ATM
kinase assays (7, 8) with either wild type ATM (odd lanes) or a KD
version (even lanes) as shown. As a control, a GST fusion protein with
Brca1 residues 1351–1552 was used (lanes 1 and 2; Ref. 11). The arrows
in lane 3 represent discrete phosphorylated species of GST-XBP1–1.
Molecular mass markers are indicated on the left in kilodaltons. Lower
molecular weight species represent degradation products that copurify
from E. coli lysates.
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cycle-regulated during early development as judged by immu-
noblotting of cell-free extracts staged at either mitosis or inter-
phase. We do observe, however, that the diffuse banding pat-
tern of X53BP1 in egg extracts is quite different from the
compact one seen for the somatic form of the protein. Whether
this reflects alternate forms of X53BP1 (i.e. isoforms or post-
translationally modified forms) remains to be determined. Be-
cause of the abundance of the protein, X53BP1 can be readily
detected throughout the cell cycle in complexes with Xp53
through reciprocal coimmunoprecipitation experiments. It ap-
pears that a very large fraction of the embryonic X53BP1 is
associated with Xp53 as judged by depletion analysis.3 Previ-
ously, it has been observed that many proteins involved in
early development are abundant in unfertilized eggs. This in-
cludes factors responsible for the rapid cell divisions that take
place in early development, including DNA replication initia-
tion proteins such as Xorc2, Xcdc6, and RPA, as well as the
Xp53 transcription factor (56, 63, 74, 75). We anticipate that
the large maternal stores of X53BP1 and Xp53 reflect a previ-
ously unappreciated role for these proteins during develop-
ment. During early Xenopus development, zygotic transcription
does not occur until the midblastula transition (70), eliminat-
ing any role for Xp53 as a transcription factor during this
window of time. Checkpoint response mechanisms are not es-
tablished until after midblastula transition, since treatment of
embryos staged prior to this with DNA-damaging agents does
not elicit a cell cycle arrest (76, 81). Nevertheless, previous
studies have implicated Xp53 in frog development (67, 71).
Based upon our findings that X53BP1 and Xp53 form com-
plexes during this time period, it is possible that X53BP1 may
influence the Xenopus developmental program and/or the biol-
ogy of p53. Unexpectedly, we failed to observe an interaction
between X53BP1 and Xp53 in somatic XTC cells. Similar
observations have been made regarding 53BP1 and p53 in
human cell lines.2 Thus, for reasons presently unclear, the
association between X53BP1 and Xp53 appears developmen-
tally regulated or restricted to germline tissue.
Our findings establish X53BP1 as a protein that is phospho-
rylated in response to DNA damage. In particular, we have
demonstrated that g-IR, an agent known to create chromo-
somal breaks, can induce the phosphorylation of X53BP1 in
vivo. We also provide evidence that the N-terminal region of
human 53BP1 is phosphorylated in response to g-IR in vivo.
Our data suggest that at least two kinases phosphorylate
X53BP1 as the protein is phosphorylated in both the absence
and the presence of g-IR DNA damage. Both the frog and
human 53BP1 orthologs contain numerous phosphorylation
sites for ATM kinase family members, particularly in their
N-terminal regions (59). This includes ATM, ATR, and DNA-
PK. Our evidence implicates ATM as one kinase that phospho-
rylates both the Xenopus and human 53BP1 proteins in vitro.
The good in vitro specificity by ATM toward GST-XBP1–1 and
GST-XBP1–4 suggests that these regions are promising tar-
gets of the kinase in vivo. Moreover, it appears that ATM can
also phosphorylate an N-terminal domain of human 53BP1 in a
DNA damage-dependent manner in vivo. Whether 53BP1 is
also targeted by ATR or DNA-PK remains to be determined.
Collectively, our data establish X53BP1 as a protein that par-
ticipates in the response to g-IR DNA damage.
Immunofluorescence experiments in asynchronous XTC cells
reveal that X53BP1 is diffuse within the cytoplasm but present
in the nucleus of a subset of cells in the form of a few large foci.
Upon exposure to g-IR, these foci appear to disperse and redis-
tribute into smaller ones throughout the nucleus. We observed
that this phenomenon occurred reproducibly in about 20% of
the cells, perhaps indicating that the g-IR-dependent dispersal
of X53BP1 nuclear foci may occur at a discrete stage within the
cell cycle, such as S phase. Presently, we cannot prove that
X53BP1 phosphorylation and its dispersal into smaller nuclear
foci in response to g-IR are related. Such X53BP1 foci increase
in number in response to g-IR possibly as a result of the protein
being localized to sites of newly created DNA damage. Previous
studies with BRCA1 have demonstrated that the protein dis-
perses from nuclear foci as a function of various DNA-damag-
ing agents, including g-IR (15). The DNA damage-dependent
dispersal of BRCA1 foci has been shown to correlate very well
with the phosphorylation of the protein (15). Notably, the Cds1/
Chk2 effector kinase has been shown to be responsible, at least
in part, for the dispersal of BRCA1 nuclear foci in response to
DNA damage (77). We hypothesize that an analogous mecha-
nism exists between 53BP1 phosphorylation and its subcellular
localization and are currently designing experiments to test
this notion.
In some respects, the general framework for the biological
response to DNA damage appears conserved from fungal sys-
tems to human. DNA damage-sensing proteins activate PI3 J. C. Morales and P. B. Carpenter, unpublished data.
FIG. 7. ATM-dependent phosphorylation of human 53BP1 in vitro and in vivo. A, in vitro kinase assay of a GST fusion protein with GST
and human 53BP1 aa 1–524 (HBP1–524). 1 mg of HBP1–524 was assayed as a substrate for either wild type ATM (lane 1) or a KD version of the
enzyme (lane 2). Lower molecular weight species are the result of degradation products commonly associated with GST fusion proteins. B, in vivo
assay for ATM-dependent phosphorylation of pZX-12-encoded FLAGBP1–524. 293T cells were transfected with 2.5 mg of pZX-12 alone (left panel)
or with an equal amount of ATM-WT (middle panel) or ATM-KD (right panel) encoding plasmids. Some samples were treated with 50 Gy of g-IR
(lanes 3, 4, 7, 8, 11, and 12). FLAGBP1–524 was isolated by immunoprecipitation and evaluated for modification by electrophoretic mobility shifts
in 6% SDS gels in the absence (odd lanes) or presence of 1.0 units of l-phosphatase (even lanes). The arrow represents FLAGBP1–524 shifted bands.
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kinase-like enzymes that transduce the damaged-DNA signal
to either effector kinases and/or transcription factors (1, 35).
The end result is an attenuation in cell cycle progression and
the activation of the DNA repair apparatus. Thus, many of the
gene products identified through yeast genetics might also be
expected to have conserved orthologs in higher eukaryotes.
This appears to be the case for many of the DNA damage
sensors (budding yeast/fission yeast Mec3/Hus1, Ddc/Rad9,
and Rad17/Rad1), PI 3-kinase-like transducers Mec1/Rad3, ef-
fector kinases Chk1/Chk1 and Rad53/Cds1, and many aspects
of the DNA repair machinery (1, 9, 25–30, 78, 80). Although
budding yeast does not utilize p53-based mechanisms for cell
cycle arrest, it activates analogous transcription-coupled repair
processes through Rad53 and Dun1 (1). Given this, one might
wonder how 53BP1 fits into any such generalized scheme, since
no obvious orthologs of the protein appear in the yeasts. How-
ever, 53BP1 contains homology to previously identified yeast
DNA damage response proteins only through its BRCT motifs.
This most notably includes budding yeast Rad9 and Dbp11 and
fission yeast Crb2 and Cut5 (1, 31, 52), all of which are thought
of as upstream regulators in the DNA damage response (1, 52).
If 53BP1 can be thought of in a similar manner, then it is
conceivable that the protein is part of the sensing mechanism
for DSBs that is transduced to ATM and/or its related family
members. We have observed that X53BP1 becomes phospho-
rylated shortly after DNA damage (within 5 min),3 consistent
with the protein functioning as part of the initial biological
response to g-IR. Whatever the case, it appears that 53BP1 is
an important player in the biological response to g-IR DNA
damage and possibly other types of genotoxic stress. The elu-
cidation of its precise role in these processes awaits further
investigation.
Acknowledgments—We are grateful to the many people who contrib-
uted to and/or supported this project throughout its various stages. In
particular, we thank Steve Elledge and David Cortez for numerous
reagents and for support throughout the course of this study. We are
grateful to Thanos Halazonetis for communicating results prior to pub-
lication. We thank Paul Mueller for use of the mitotic catastrophe
screen and Dr. David Lane for the kind gift of Xenopus p53 antisera. We
are indebted to Dr. Andrew Krieg for the gift of Xenopus EF-1a for
Northern loading controls and to Dr. Ronald Kerman for permission to
use the cesium irradiator. We also thank Tamara Tripic and Jason
Grier for their efforts during the earlier stages of the project. We are
also indebted to Rob Kirken and Mike Blackburn for experimental
advice and assistance with the use of the fluorescence microscope,
respectively.
REFERENCES
1. Elledge, S. J. (1996) Science 274, 1664–1672
2. Hartwell, L. H., and Kastan, M. B. (1994) Science 266, 1821–1828
3. Savitsky, K., Bar-Shira, S., Gilad, S., Rotman, G., Ziv, Y., Vanagaite, L., Tagle,
D. A., Smith, S., Uzeil, T., and Sfez, S. (1995) Science 268, 1749–1753
4. Painter, R. B., and Young, B. R. (1980) Proc. Natl. Acad. Sci. U. S. A. 77,
7315–7317
5. Lavin, M. F., and Shiloh, Y. (1997) Annu. Rev. Immunol. 15, 177–202
6. Futreal, P. A., Liu, Q., Shattuck-Eidens, D., Cochran, C., Harshmann, K., et al.
(1994) Science 266, 120–122
7. Banin, S., S.-Y. Shieh, Taya, Y., Anderson, C. W., Chessa, L., Smorodinsky,
N. I., Prives, C., Reiss, Y., Shiloh, Y., and Ziv, Y. (1998) Science 281,
1674–1677
8. Canman, C. E., Lim, D.-S., Cimprich, K. A., Taya, Y., Tamia, K., Sakaguchi, K.,
Appella, E., Kastan, M. B., and Siliciano, J. D. (1998) Science 281,
1677–1680
9. Matsuoka, S., Huang, M., and Elledge, S. J. (1998) Science 282, 1893–1897
10. Bell, D. W., Varley, J. M., Szydlo, T. E., Kang, D. H., Wahrer, D. C. R.,
Shannon, K. E., Lubratovich, M., Verselis, S. J., Isselbacher, K. J., Fraum-
eni, J. F., Birch, J. M., Li, F. P., Garber, J. E., and Haber, D. A. (1999)
Science 286, 2528–2531
11. Cortez, D., Wang, Y., Qin, J., and Elledge, S. J. (1999) Science 286, 1162–1166
12. Lim, D.-S., Kim, S-T., Xu, B., Maser, R. S., Lin, J., Petrini, J. H. J., and Kastan,
M. B. (2000) Nature 404, 613–617
13. Wu, X., Ranganathan, V., Weisman, D. S., Heine, W. F., Ciccone, D. N.,
O’Neill, T. B., Crick, K. E., Pierce, K. A., Lane, W. S., Rathbun, G., Living-
ston, D. M., and Weaver, D. T. (2000) Nature 405, 477–481
14. Zhao, S., Weng, Y.-C., Yuan, S.-S. F., Lin, Y.-T., Hsu, H.-C., Lin, S.-C. J.,
Gerbino, E., Song, M.-h, Zdzienicka, Z., Gatt, R. A., Shay, J. W., Ziv, Y.,
Shiolh, Y., and Lee, E. Y.-H. P. (2000) Nature 405, 473–477
15. Scully, R., Anderson, S. F., Chao, D. M., Wei, W., Ye, L., Young, R. A.,
Livingston, D. M., and Parvin, J. D. (1997) Proc. Natl. Acad. Sci. U. S. A. 94,
5605–5610
16. Gowen, L. C., Avrutskaya, A. V., Latour, A. M., Koller, B. H., and Leadon, S.
A. (1998) Science 281, 1009–1012
17. Moynahan, M. E., Chiu, J. W., Koller, B. H., and Jasin, M. (1999) Mol. Cell 4,
511–518
18. Xu, X., Weave, Z., Linke, S. P., Li, C., Gotay, J., Wang, X. W., Harris, C. C.,
Ried, T., and Deng, C. X. (1999) Mol. Cell 3, 389–395
19. Wang, Y. Cortez, D., Yazdi, P., Neff, N., Elledge, S. J., and Qin, J. (2000) Genes
Dev. 14, 927–939
20. Wang, H., and Elledge, S. J. (1999) Proc. Natl. Acad. Sci. U. S. A. 96,
3824–3829
21. Haber, J. E. (1998) Cell 95, 583–586
22. Petrini, J. H. J. (2000) Curr. Opin. Cell Biol. 12, 293–296
23. Murakami, H., and Okayama, H. (1995) Nature 374, 817–819
24. O’Connell, M. J., Walworth, N. C., and Carr, A. M. (2000) Trends Cell Biol. 7,
296–303
25. Al-Khodairy, F., Foton, E., Sheldrick, K. S., Griffiths, D. J., Lehmann, A. R.,
and Carr, A. M. (1994) Mol. Biol. Cell 5, 147–160
26. Brown, A. L., Lee, C. H., Schwarz, J. K., Mitiku, N., Piwnica-Worms, H., and
Chung, J. H. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 3745–3750
27. Blasina, A. D., Weyer, D., Laus, M. C., Luyten, W. H., Parker, A. E., and
McGowan, C. H. (1999) Curr. Biol. 9, 1–10
28. Kumagai, A., Guo, Z., Emani, K. H., Wang, S. X., and Dunphy, W. G. (1998)
J. Cell Biol. 142, 1559–1569
29. Chaturverdi, P., Eng, W. K., Zhu, M. R., Mattern, R., Mishra, M. R., Hurle,
M. R., Zhang, X., Annan, R. S., Lu, Q., Faucette, L. F., et al. (1999) Oncogene
18, 4047–4054
30. Kumagai, A., and Dunphy, W. G. (1999) Genes Dev. 13, 1067–1072
31. Weinert, T. A., and Hartwell, L. H. (1988) Science 241, 317–322
32. Paulovich, A. G., and Hartwell, L. H. (1995) Cell 82, 841–847
33. Siede, W., Friedberg, A. S., and Friedberg, E. C. (1993) Proc. Natl. Acad. Sci.
U. S. A. 90, 7985–7989
34. Yang, S. S., Yeh, E., Salmon, E. D., and Bloom, K. (1997) J. Cell Biol. 136,
345–354
35. Sanchez, Y., Wong, C., Thoma, R. S., Richman, R., Wu, Z., Piwnica-Worms, H.,
and Elledge, S. J. (1997) Science 277, 1497–1501
36. Shimomura, T., Ando, S., Matsumoto, K., and Sugimoto, K. (1998) Mol. Cell.
Biol. 18, 5485–5491
37. Griffiths, D. J., Barbet, N. C., McCready, S., Lehmann, A. R., and Carr, A. M.
(1995) EMBO J. 14, 5812–5823
38. Caspari, T., Dahlen, M., Kanter-Smoler, G., Lindsay, H. D., Hofman, K.,
Papadimitriou, K., Sunnerhagen, P., and Carr, A. M. (2000) Mol. Cell. Biol.
20, 1254–1262
39. Thelen, M. P., Venclovas, C., and Fidelis, K. (1999) Cell 96, 769–770
40. Bessho, T., and Sancar, A. (2000) J. Biol. Chem. 275, 7451–7454
41. Halazonetis, T. D., and Shiloh, Y. (1999) Biochem. Biophys. Acta 1424, 45–55
42. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W.
(1991) Cancer Res. 51, 6304–6311
43. Kastan, M. B., Zhan, Q., El-Diery, W., Carrier, F., Jacks, T., Walsh, W. V.,
Plunkett, B. S., Vogelstein, B., and Fornace, A. J. (1992) Cell 71, 587–597
44. Giaccia, A. J., and Kastan, M. B. (1998) Genes Dev. 12, 2973–2983
45. Levine, A. J. (1997) Cell 88, 323–331
46. Chehab, N. H., Malikzay, A., Appel, M., and Halazonetis, T. D. (2000) Genes
Dev. 14, 278–288
47. Shieh, S.-Y., Ahn, J., Tamia, K., Taya, Y., and Prives, C. (2000) Genes Dev. 14,
289–300
48. Iwabuchi, K., Bartel, P. L., Li, B., Maraaccino, R., and Fields, S. (1994) Proc.
Natl. Acad. Sci. U. S. A. 91, 6098–6102
49. Callebaut, I., and Mornon, J. (1997) FEBS Lett. 400, 25–30
50. Bork, P., Hoffman, K., Bucher, P., Neuwald, A. F., Altschul, S. F., and Koonin,
E. V. (1997) FASEB J. 11, 68–76
51. Zhang, X., Morera, S., Bates, P. A., Whitehead, P. C., Coffer, A. I., Hainbucher,
K., Nash, R., Sternberg, M. J. E., Lindahl, T., and Freemont, P. S. (1998)
EMBO J. 17, 6404–6411
52. Saka, Y., Esashi, F., Matsusaka, T., Mochida, S., and Yanagida, M. (1997)
Genes Dev. 11, 3387–3400
53. Murray, A. W. (1991) Methods Cell Biol. 36, 581–605
54. Datta, B., Li, B., Choubey, D., Nallur, G., and Lengyel, P. (1996) J. Biol. Chem.
271, 27544–27555
55. Lundgren, K., Walworth, N., Booher, R., Dembski, M., Kirschner, M., and
Beach, D. (1991) Cell 64, 1111–1122
56. Carpenter, P. B., Mueller, P. R., and Dunphy, W. G. (1996) Nature 379,
357–360
57. Morgan, D. O. (1997) Annu. Rev. Cell Dev. Biol. 13, 261–291
58. Iwabuchi, K., Li, B., Massa, H. F., Trask, B. J., Date, T., and Fields, S. (1998)
J. Biol. Chem. 273, 26061–26068
59. Kim, S.-T., Lim, D.-S., Canman, C. E., and Kastan, M. B. (1999) J. Biol. Chem.
274, 37538–37543
60. Mueller, P. R., Coleman, T. R., and Dunphy, W. G. (1995) Mol. Biol. Cell 6,
119–134
61. Koonin, E. V., Altschul, S. F., and Bork, P. (1996) Nat. Genet. 13, 266–267
62. Krieg, P. A., Varnum, S. M., Wormington, W. M., and Melton, D. A. (1989) Dev.
Biol. 133, 93–100
63. Amariglio, F., Tchang, F., Prioleau, M.-N., Soussi, T., Cibert, C., and Mechali,
M. (1997) Oncogene 15, 2191–2199
64. Scully, R., Chen, J., Plug, A., Xiao, Y., Weaver, D., Feunteun, J., Ashley, T.,
and Livingston, D. M. (1997) Cell 88, 265–275
65. Soussi, T., de Fromentel, C. C., Mechali, M., May, P., and Kress, M. (1987)
Oncogene 1, 71–78
66. Cox, L. S., Midgley, C. A., and Lane, D. P. (1994) Oncogene 10, 2951–2959
53BP1 and the DNA Damage Response 2717
67. Hoever, M., Clement, J. H., Wedlich, D., Montenarh, M., Knoechel, W. (1994)
Oncogene 9, 109–120
68. Tchang, F., Gusse, M., Soussi, T., and Mechali, M. (1993) Dev. Biol. 159,
163–172
69. Wang, Y., Farmer, G., Soussi, T., and Prives, C. (1995) Oncogene 10, 779–784
70. Newport, J., and Kirschner, M. (1982) Cell 30, 675–686
71. Wallingford, J. B., Seufert, D. W., Virta, V. C., and Vize, P. D. (1997) Curr.
Biol. 10, 747–757
72. Carpenter, P. B., and Dunphy, W. G. (1998) J. Biol. Chem. 273, 24891–24897
73. Humphrey, J. S., Salim, A., Erdos, M. R., Collins, F. S., Brody, L. C., and
Klausner, R. D. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 5820–5825
74. Adachi, Y., and Laemmli, U. K. (1992) J. Cell Biol. 119, 1–15
75. Coleman, T. R., Carpenter, P. B., and Dunphy, W. G. (1996) Cell 87, 53–63
76. Clute, P., and Masui, Y. (1997) Dev. Biol. 185, 1–13
77. Lee, J.-S., Collins, K. M., Brown, A. L., Lee, C.-H., and Chung, J. H. (2000)
Nature 404, 201–204
78. Liu, Q., Guntuku, S., Cui, X. S., Matsuoka S., Cortez, D., Tamai, K., Luo, G.,
Rivera0S. C., DeMayo, F., Bradley, A., Donehower, L. A., and Elledge, S. J.
(2000) Genes Dev. 14, 1448–1459
79. Smith, J. C., and Tata, J. R. (1991) Methods Cell Biol. 36, 636–654
80. Fogarty, P., Campbell, S. D., Abu-Shumays, R. A., Phalle, B. S., Yu, K. R., Uy,
G. L., Goldberg, M. L., and Sullivan, W. (1997) Curr. Biol. 7, 418–426
81. Anderson, J. A., Lewellyn, A. L., and Maller, J. L. (1997) Mol. Biol. Cell 8,
1195–1206
53BP1 and the DNA Damage Response2718
